Zobrazeno 1 - 10
of 15
pro vyhledávání: '"John Zielinski"'
Autor:
Nadia Luheshi, Joshua P. Frederick, Ronald Herbst, Robert W. Wilkinson, Maja Sedic, Chris Morehouse, Han Si, Jean-Martin Lapointe, Philip Martin, Chris Bagnall, Michal Sulikowski, Steve Novick, David A. Leinster, Gordon Moody, Darren Potz, Katharina Deschler, Grace Adjei, Kathy Mulgrew, Eleanor Clancy-Thompson, James Moynihan, Kristen Arnold, Amanda Watkins, Sushma Gurumurthy, Ankita Mishra, Fabien Garcon, Shannon Burke, Russell Karp, Faith Musenge, Ameya Apte, John Zielinski, Dyane Bailey, Susannah L. Hewitt
Supplementary Figures S1-S11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::447a2faa43430fbac4574cf80676b109
https://doi.org/10.1158/1078-0432.22477526
https://doi.org/10.1158/1078-0432.22477526
Autor:
Nadia Luheshi, Joshua P. Frederick, Ronald Herbst, Robert W. Wilkinson, Maja Sedic, Chris Morehouse, Han Si, Jean-Martin Lapointe, Philip Martin, Chris Bagnall, Michal Sulikowski, Steve Novick, David A. Leinster, Gordon Moody, Darren Potz, Katharina Deschler, Grace Adjei, Kathy Mulgrew, Eleanor Clancy-Thompson, James Moynihan, Kristen Arnold, Amanda Watkins, Sushma Gurumurthy, Ankita Mishra, Fabien Garcon, Shannon Burke, Russell Karp, Faith Musenge, Ameya Apte, John Zielinski, Dyane Bailey, Susannah L. Hewitt
Purpose:While immune checkpoint inhibitors such as anti–PD-L1 are rapidly becoming the standard of care in the treatment of many cancers, only a subset of treated patients have long-term responses. IL12 promotes antitumor immunity in mouse models;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b977133483ab014e3abfe875a2074603
https://doi.org/10.1158/1078-0432.c.6529685
https://doi.org/10.1158/1078-0432.c.6529685
Autor:
Nadia Luheshi, Joshua P. Frederick, Ronald Herbst, Robert W. Wilkinson, Maja Sedic, Chris Morehouse, Han Si, Jean-Martin Lapointe, Philip Martin, Chris Bagnall, Michal Sulikowski, Steve Novick, David A. Leinster, Gordon Moody, Darren Potz, Katharina Deschler, Grace Adjei, Kathy Mulgrew, Eleanor Clancy-Thompson, James Moynihan, Kristen Arnold, Amanda Watkins, Sushma Gurumurthy, Ankita Mishra, Fabien Garcon, Shannon Burke, Russell Karp, Faith Musenge, Ameya Apte, John Zielinski, Dyane Bailey, Susannah L. Hewitt
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18e329b32ceccaccb01d825f32846ab6
https://doi.org/10.1158/1078-0432.22477523
https://doi.org/10.1158/1078-0432.22477523
Autor:
Kristen Arnold, Chris Morehouse, Eleanor Clancy-Thompson, Katharina Deschler, Susannah Hewitt, Russell Karp, Ameya Apte, Chris Bagnall, Faith Musenge, Darren Potz, David A. Leinster, Kathy Mulgrew, Ankita Mishra, Gordon Moody, Maja Sedic, Joshua Frederick, John Zielinski, Fabien Garcon, Sushma Gurumurthy, Nadia Luheshi, Michal Sulikowski, Steve Novick, Han Si, Philip Martin, Grace Adjei, James Moynihan, Jean-Martin Lapointe, Amanda Watkins, Shannon Burke, Ronald Herbst, Dyane Bailey, Robert W. Wilkinson
Publikováno v:
Clinical Cancer Research. 26:6284-6298
Purpose: While immune checkpoint inhibitors such as anti–PD-L1 are rapidly becoming the standard of care in the treatment of many cancers, only a subset of treated patients have long-term responses. IL12 promotes antitumor immunity in mouse models;
Autor:
Ashley Davis, Kristen Arnold, Russell Karp, Maria S. Iliou, Khushbu Bhatt, John Zielinski, Joshua Frederick, Ameya Apte, Maija Garnaas, Samuel J. Farlow, Sima Zacharek, Nikhil Khatwani, Dyane Bailey, Kana Ichikawa, Ailin Bai, Faith Musenge, Susannah Hewitt, Stephen V. Su, Graham MacLean, Kristin E. Burke
Publikováno v:
Science Translational Medicine. 11
Many solid cancers contain dysfunctional immune microenvironments. Immune system modulators that initiate responses to foreign pathogens could be promising candidates for reigniting productive responses toward tumors. Interleukin-1 (IL-1) and IL-12 c
Autor:
Jean-Martin Lapointe, Robert W. Wilkinson, Kristen Arnold, Michael Sulikowski, Han Si, Fabien Garcon, Amanda Watkins, Joshua Frederick, Ronald Herbst, Nadia Luheshi, John Zielinski, Susannah Hewitt, Christopher Morehouse, Christopher Bagnall, Philip Martin, Gordon Moody, Shannon Burke
Publikováno v:
Cancer Research. 79:5017-5017
Patients who respond to PD-L1 / PD-1 immune checkpoint blockade tend to have an inflamed, TH1 polarised tumor microenvironment (TME), characterised by expression of interferon-γ (IFNγ) and PD-L1. Novel therapies that induce TH1 transformation of th
Autor:
Michael John Zielinski
Publikováno v:
Actas de Arquitectura Religiosa Contemporánea. 3:268-277
El espacio liturgico no puede evitar dar testimonio del milagro de la Presencia, y solo puede hacerlo por sus propios medios: a traves de la evidencia de masas estructurales, de la combinacion de materiales, texturas, colores; de la combinacion armon
Autor:
Darren Potz, Susannah Hewitt, Ronald Herbst, John Zielinski, Kristen Arnold, Robert W. Wilkinson, Ameya Apte, Sushma Gurumurthy, Ankita Mishra, Russell Karp, Andrew Leinster, Dyane Bailey, Faith Musenge, Joshua Frederick, Nadia Luheshi, Grace Adjei
Publikováno v:
Cancer Research. 78:1758-1758
As a central mediator of TH1 immune responses, interleukin 12 (IL-12) in the tumor microenvironment (TME) plays a key role in driving anti-tumor immunity. Recombinant IL-12 has been reported to promote CD8+ cytotoxic T cell (CTL) dependent anti-tumor
Autor:
Kana Ichikawa, Kristen Arnold, Steve M. Kelsey, Kerry Benenato, Russ Karp, Maja Sedic, Graham MacLean, Josh Frederick, Ailin Bai, Darren Potz, Susannah Hewitt, Ameya Apte, Bo Ying, Dyane Bailey, John Zielinski, Samuel J. Farlow
Publikováno v:
Cancer Research. 77:1607-1607
Immunologic responses to cancer involve complex interactions of cells within the tumor microenvironment (TME). These interactions are mediated in part through co-stimulatory and inhibitory transmembrane proteins, cytokines and chemokines. Direct intr
Autor:
Guido Forni, Wei Zen Wei, Richard F. Jones, Jennifer B. Jacob, Olga Radkevich, John Zielinski, David Shim
Publikováno v:
Cellular immunology. 240(2)
To assess the efficacy of self versus heterologous ErbB-2 vaccines, the reactivity to human and rat ErbB-2 (Her-2 and neu, respectively) DNA vaccines were tested in normal, Her-2 or neu transgenic mice. When immunized with either Her-2 or neu DNA, no